Sign In
Buy EVH
$3.78
-0.180 (-4.55%)
At Close: Jun 03, 2026
Evolent dips after Truist warns guidance may be 'significantly' below consensus
03:59pm, Wednesday, 15'th Jan 2025
Truist analyst Jailendra Singh caught up with Evolent Health post its presentation at an investor healthcare conference and also noted that the company released an 8-K earlier in the week outlining so
Evolent announces Dr. Von Nguyen as incoming Chief Medical Officer, effective January 1
04:10pm, Wednesday, 18'th Dec 2024
Longtime CMO Dr. Andrew Hertler to serve as senior advisor and CMO emeritus. WASHINGTON , Dec. 18, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health o
New Strong Sell Stocks for December 12th
05:16am, Thursday, 12'th Dec 2024
ASH, BIDU and EVH have been added to the Zacks Rank #5 (Strong Sell) List on December 12, 2024.
Evolent Health: A Shot At Revival After Market Bruising
02:37am, Tuesday, 12'th Nov 2024
Evolent Health has seen a significant 50% drop due to a Q3 earnings miss and high medical costs. Despite setbacks, Evolent secured record-breaking new business deals and anticipates over 15% annual re
Evolent Health, Inc. (EVH) Q3 2024 Earnings Call Transcript
09:12am, Saturday, 09'th Nov 2024
Evolent Health, Inc. (NYSE:EVH ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Participants Seth Blackley - Chief Executive Officer John Johnson - Chief Financial Officer Seth Frank - V
Compared to Estimates, Evolent Health (EVH) Q3 Earnings: A Look at Key Metrics
04:30pm, Friday, 08'th Nov 2024
The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Stree
U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.2% on Friday.
Evolent Health (EVH) Q3 Earnings and Revenues Lag Estimates
07:00pm, Thursday, 07'th Nov 2024
Evolent Health (EVH) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.30 per share. This compares to earnings of $0.30 per share a year ago.
Evolent Announces Third Quarter 2024 Results
04:10pm, Thursday, 07'th Nov 2024
Revenue of $621.4 million, an increase of $110.4 million or 21.6%, from the three months ended September 30, 2023. Net loss attributable to common shareholders of Evolent Health, Inc. of $(31.2) milli
Unlocking Q3 Potential of Evolent Health (EVH): Exploring Wall Street Estimates for Key Metrics
10:20am, Wednesday, 06'th Nov 2024
Beyond analysts' top -and-bottom-line estimates for Evolent Health (EVH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the q
Why Evolent Health (EVH) is Poised to Beat Earnings Estimates Again
01:11pm, Tuesday, 05'th Nov 2024
Evolent Health (EVH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Evolent Health (EVH) Reports Next Week: What to Know Ahead of the Release
11:06am, Thursday, 31'st Oct 2024
Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evolent To Release Third Quarter 2024 Financial Results on Thursday, November 7, 2024
08:00am, Friday, 11'th Oct 2024
Company to Participate in Upcoming Conferences WASHINGTON , Oct. 11, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex
Evolent Health Inc (EVH) Stock Price Down 3.2% on Oct 2
12:08pm, Wednesday, 02'nd Oct 2024
Shares of Evolent Health Inc (EVH, Financial) fell 3.20% in mid-day trading on Oct 2. The stock reached an intraday low of $25.76, before recovering slightly to $26.19, down from its previous close of
Evolent Health: Let The Bidding Begin
09:00am, Friday, 23'rd Aug 2024
Evolent Health is potentially being taken private at a bid of $3.8 billion, offering a 15% upside to the stock at $32 per share. The company's revenue growth rates are expected to decelerate, but pote
